The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...
Hosted on MSN
Cracking cancer's code: Research identifies novel drug target for acute myeloid leukemia treatment
Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors ...
Bio-Path Holdings ((BPTH)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Moleculin Biotech, Inc. announced that the World Health Organization has approved “naxtarubicin” as the non-proprietary name for its next-generation anthracycline, Annamycin, which is being developed ...
Tatiana Schlossberg, President John F. Kennedy's granddaughter, has died. Here's what to know about acute myeloid leukemia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback